Nanobodies and Heavy-Chain Only Gene-Deited Mouse (KY-HC Mouse Model)
Nanobodies and Heavy-Chain Only Gene-Deited Mouse (KY-HC Mouse Model) Overview
Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease diagnosis and treatment. These unique antibodies typically originate from the variable region of heavy chain antibodies, a feature distinguishing them from traditional antibodies due to the absence of light chains and the CH1 domain of heavy chains, as seen in camelid animals.
Our company has pioneered a HC mouse model, exclusively engineered to produce heavy chain antibodies through advanced gene editing technology. Following immunization, these mice yield highly diverse antibody libraries, with the selected antibodies exhibiting affinity levels comparable to conventional nanobodies. The HC mouse model effectively addresses challenges related to the demanding breeding conditions of camelids and the associated high immunization costs. This enables our customers to conduct nanobody screening with reduced expenses, streamlining the process.
All Antibody Discovery Services
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.
